畅通政策传导渠道 每年岁末年初，政府搭台，推动国谈药品与定点医药机构对接，这在上海已成为常态。 作为今年上海推动国谈创新药落地的首场重要活动，本次推介会聚焦新进医保目录的"新优药械"， 围绕入院应用关键环节，搭建起"政府—医院—企业"三方联动沟通平台，破解创新药入院流程烦琐、信 息不对称等痛点难点问题。 为加快创新产品应用推广，2022年，由市生物医药产业主管部门牵头，联合市卫健委、市医保局、 申康中心等部门，建立了支持地产新药入院应用绿色通道的工作机制《上海市生物医药"新优药械"产品 目录》（以下简称《目录》）。截至2025年底，《目录》已发布7批次，纳入220件产品，产品总销售额 逐年提高，促进入院作用明显。 记者 周程祎 林子璐 2025版国家医保药品目录已于今年1月1日正式执行，这是国家医保局成立以来的第八次目录调整。 本次调整新增药品114种，其中一类创新药达50种，涵盖肿瘤、罕见病、慢性病等多个治疗领域，为临 床用药提供了更多选择。 如何加速创新药临床应用落地，惠及更多患者？在15日举行的上海市2026年首场新增国谈创新药推 介会上，政府、医院、药企三方代表再次坐到了一起，探讨新产品，共话新机遇。 ...

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Yinuo Pharmaceutical-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s product, Icosapent Ethyl, is now recognized as the first domestically developed long-acting GLP-1 receptor agonist in China [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list is aimed at improving the accessibility of innovative diabetes medications [1] - The 2025 National Guidelines for Diabetes Prevention and Management highlight Icosapent Ethyl as a key treatment option for adult patients with type 2 diabetes, especially those with cardiovascular disease risk factors, heart failure, chronic kidney disease, and obesity [1]

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Silver诺医药-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s drug, Icosapent Ethyl, is now officially recognized for the treatment of blood sugar control in adult patients with type 2 diabetes, effective from January 1, 2026 [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the National Medical Insurance Drug List is a crucial advancement for the accessibility of innovative diabetes treatments in China [1] - The "National Guidelines for Diabetes Prevention and Management (2025)" lists Icosapent Ethyl as a key injectable GLP-1RA, providing policy and regulatory support for its use in primary healthcare settings [1] - The guidelines emphasize the importance of GLP-1RA for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of more than 25% in the two days following its inclusion in the Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, the stock price of Silver诺医药-B is reported at 39.44 HKD, reflecting a rise of 23.38% with a trading volume of 76.49 million HKD [1] Group 2: Inclusion in Stock Connect - The company announced that its H shares have been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the investor base and increase the trading liquidity of H shares, thereby enhancing the investment value and market reputation of the company [1] Group 3: Product Development - Silver诺医药-B has announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 2,062.3 million [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94%, China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3] - The light communication sector saw significant gains, with Huiju Technology rising over 7% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and moderately open up capital space and leverage limits, which could benefit leading brokerages [4] New Listings and Stock Movements - Two new stocks were listed, with Zhuoyue Ruixin (02687) surging 87.26% and Naxinwei (02676) declining 4.31% [7] - Restructured Energy (02570) faced a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) saw a decline of 14.32% following its inclusion in the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major order from FAW Toyota [10] Pharmaceutical Sector Updates - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, up from 76% in 2024 [6]

Core Viewpoint - The article highlights the journey of Wang Qinghua, a scientist turned entrepreneur, who founded Yinnuo Pharmaceutical to develop innovative treatments for metabolic diseases, particularly focusing on the GLP-1 receptor agonist, Irsu Paglutide α, which has recently gained market approval and is positioned to disrupt the existing market dominated by foreign competitors [5][9][12]. Company Overview - Yinnuo Pharmaceutical was established in 2014 by Wang Qinghua, who has over a decade of research experience in GLP-1 molecular engineering. The company focuses on developing drugs for metabolic diseases, particularly diabetes [5][8]. - The company’s flagship product, Irsu Paglutide α (marketed as Yinuo Qing), is the first original human long-acting GLP-1 receptor agonist in Asia to reach the registration approval stage, with approval granted in January 2025 [6][9]. Product Development and Market Entry - Irsu Paglutide α has shown promising results, achieving sales of 38.14 million yuan within the first five months of its launch, breaking the company's decade-long revenue drought [6][11]. - The product is priced 30%-50% lower than similar imported products, enhancing its competitive edge in the market [11]. Financial Performance - Yinnuo Pharmaceutical has faced significant financial challenges, with a cumulative investment exceeding 1 billion yuan over ten years. However, the company is transitioning from heavy R&D spending to a more sustainable commercial model [11][12]. - The company reported a net loss of 733 million yuan in 2023, which is expected to narrow significantly to 175 million yuan in 2024, indicating a positive shift in financial health [11]. Competitive Landscape - The GLP-1 market is highly competitive, with major players like Novo Nordisk and Eli Lilly dominating 90% of the weight-loss drug market. Yinnuo aims to differentiate itself through the unique efficacy of Irsu Paglutide α and plans to expand its production capabilities [14][15]. - The company has a robust pipeline with multiple candidates in various stages of development, including treatments for obesity and metabolic dysfunction-related fatty liver disease [10][12]. Investment and Valuation - Yinnuo has successfully completed four rounds of financing, with its valuation soaring from 666 million yuan in the Pre-A round to 4.65 billion yuan in the B+ round, raising a total of 1.558 billion yuan [13][15]. - The company plans to utilize funds from its recent IPO to expand its indications, enhance global patent strategies, and develop oral formulations to compete with other market players [15].

Group 1 - The new listing rules of the Hong Kong Stock Exchange took effect on August 4, focusing on IPO issuance and pricing mechanisms, as well as public market regulations [1] - Silver诺医药-B (HK02591) experienced significant market interest during its subscription phase, with over 250,000 investors participating and nearly HKD 300 billion frozen in subscriptions [1] - On August 15, Silver诺医药 officially listed on the Hong Kong Stock Exchange at a price of HKD 18.68 per share, with an opening price that surged over 200%, closing with a gain of 206.48% [3] Group 2 - The new rules allow new listing applicants to choose between Mechanism A or Mechanism B for public subscription distribution, with Mechanism B allowing a fixed allocation of 10% to 60% for public offerings [4] - Silver诺医药 opted for Mechanism B, allocating only 10% of its shares for public sale, resulting in a significantly lower chance of winning shares for retail investors [4][5] - The company received 5,341.66 times the subscription demand, but only 0.5% of investors successfully obtained shares, with only 18,300 out of over 250,000 participants winning shares [5] Group 3 - Silver诺医药 focuses on innovative therapies for diabetes and other metabolic diseases, with its core product, Irsuglutide α (brand name: Yinuo Qing), being referred to as "domestic Semaglutide" [6] - Despite the commercialization of Irsuglutide α, the company faces intense market competition, with three long-acting GLP-1 receptor agonists expected to capture 83% of the global GLP-1 therapy market by 2024 [6] - The company is also advancing clinical trials for its core product targeting obesity, amidst a competitive landscape with 51 GLP-1 receptor agonist candidates in clinical development in China [6]

Group 1 - The core product of the company, Isu-Paglutide α, has been approved by the National Medical Products Administration and was commercialized in February 2023, making it the first domestically developed long-acting GLP-1 drug with independent intellectual property rights [3] - The company experienced a significant market response upon its IPO, with a subscription rate of 5341.66 times, raising approximately 6.347 billion HKD from the issuance of 36.56 million shares at a price of 18.68 HKD per share [1] - The company plans to allocate approximately 90% of the funds raised from the IPO to ongoing and planned clinical trials, as well as the commercialization of Isu-Paglutide α, including further clinical research for indication expansion [1] Group 2 - The company was established in 2014 and focuses on developing treatments for obesity, overweight, and metabolic dysfunction-related fatty liver disease (MASH) [2] - The company has not yet achieved profitability, with projected losses of 733 million CNY in 2023, 175 million CNY in 2024, and 97.88 million CNY by May 2025, while generating revenue of 38.1 million CNY from Isu-Paglutide α sales [3] - The company has conducted four rounds of financing from 2020 to 2024, raising a total of approximately 1.558 billion CNY, all directed towards the research and development of Isu-Paglutide α [1][2]

Core Viewpoint - Silver诺医药 is attempting a second IPO in Hong Kong, driven by the launch of its diabetes drug, I苏帕格鲁肽α, which has ended the company's decade-long revenue drought and is pivotal to its valuation of 46 billion yuan [2][4]. Group 1: Company Overview - Silver诺医药 has not generated actual sales revenue since its establishment, with cumulative losses of 1.204 billion yuan from 2022 to 2024 [4]. - The company has relied heavily on external financing, raising a total of 1.558 billion yuan from 2020 to 2024, with notable investors including 中金资本 and 淡马锡 [4][5]. - The company’s R&D expenses were 492 million yuan and 103 million yuan for 2023 and 2024, respectively, with the core product accounting for 76.4% and 95.7% of total expenditures [4]. Group 2: Market Position and Competition - The GLP-1 market is highly competitive, with 11 domestic companies in phase III trials, and Silver诺医药 may face price competition without effective data [5][6]. - As of June 5, there are 51 GLP-1 receptor agonists in clinical development in China, with 22 being long-acting human GLP-1 receptor agonists [6]. - Silver诺医药's I苏帕格鲁肽α is lagging in the development of weight loss indications, with plans to start phase IIb/III trials in March 2025 [6]. Group 3: Financial Strategy and Future Plans - The company has implemented cost-cutting measures, reducing administrative expenses from 256 million yuan in 2023 to 84.46 million yuan in 2024, a decrease of 67% [5]. - The IPO proceeds will allocate 90% for clinical trials and commercialization of core products, with 10% for working capital and general corporate purposes [7].

Core Viewpoint - The article discusses the second IPO attempt of Yino Pharmaceutical, focusing on its weight-loss drug, Ibusparaglutide α, and whether it can support a valuation of 4.65 billion yuan [2][3]. Group 1: Company Overview - Yino Pharmaceutical is the first domestic company to have an independently developed long-acting GLP-1 drug, Ibusparaglutide α, which has recently been approved for sale [2]. - The company has not generated any revenue since its establishment and has accumulated losses of 1.204 billion yuan from 2022 to 2024 [5]. - The company has relied heavily on external financing, raising a total of 1.558 billion yuan from various investors between 2020 and 2024 [4]. Group 2: Financial Performance - The company's valuation increased sixfold from 2021 to 2024, reaching 4.65 billion yuan, but the IPO price represents a discount of 34.97% from this valuation [3]. - The R&D expenses for Ibusparaglutide α accounted for 76.4% and 95.7% of total expenditures in 2023 and 2024, respectively [5]. - The company reported a significant reduction in administrative expenses, from 256 million yuan in 2023 to 84.46 million yuan in 2024, a decrease of 67% [7]. Group 3: Market Position and Competition - The GLP-1 market is highly competitive, with 11 domestic companies entering Phase III trials, and Yino Pharmaceutical may need to engage in price competition if it lacks effective data [6]. - The company plans to initiate Phase IIb/III clinical trials for weight-loss indications in March 2025, with completion expected in 2026 [9]. - Yino Pharmaceutical's production strategy relies on contract development and manufacturing organizations (CDMO), which helps alleviate cash flow pressure but limits scalability [9]. Group 4: Future Prospects - The company has established a commercialization team and appointed a former executive from AstraZeneca to lead its business development efforts [10]. - The net proceeds from the IPO will allocate 90% for clinical trials and commercialization of core products, with 10% for working capital and general corporate purposes [11].